Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from β-blockers and prostaglandin analogs

Clinical Ophthalmology

Volumn 6, Issue 1, 2012, Pages 231-235

  Inoue, Kenji ^a   Setogawa, Akira ^a   Higa, Risako ^a   Moriyama, Ryo ^a   Wakakura, Masato ^a   Tomita, Goji ^b  

^a Nishikasai Inouye Eye Hospital   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

blockers; Change; Intraocular pressure; Prostaglandin analog; Travoprost 0.004 timolol maleate 0.5 fixed combination

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARTEOLOL; EYE DROPS; LATANOPROST; LEVOBUNOLOL; NIPRADILOL; PROSTAGLANDIN DERIVATIVE; TAFLUPROST; TIMOLOL; TIMOLOL PLUS TRAVOPROST; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

ABNORMAL SENSATION; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; APPLICATION SITE DRYNESS; APPLICATION SITE REACTION; APPLICATION SITE STINGING; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; HYPEREMIA; INTRAOCULAR PRESSURE; IRITIS; MALE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PROSPECTIVE STUDY; QUESTIONNAIRE;

EID: 84857085152     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S29062     Document Type: Article

References (10)

1. Djafari F, Lesk MR, Harasymowycz PJ, Desjardins D, Lachaine J. Determinants of adherence to glaucoma medical therapy in long-term patient population. J Glaucoma. 2009;18(3):238-243.
2. Rhee DJ, Peace JH, Mallick S, Landry TA, Bergamini MVW; the study group. A study of the safety and efficacy of travoprost 0.004%/ timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol. 2008;2(2):313-319.
3. Arend KO, Raber T. Observational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in Germany. J Ocul Pharmacol Ther. 2008;24(4):414-420.
4. Rossi GC, Pasinetti GM, Bracchino M, et al. Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study. Expert Opin Pharmocother. 2009;10(11):1705-1711.
5. Scherzer ML, Liehneova I, Negrete FJ, Schnober D. Travoprost 0.004%/ timolol 0.5% fixed combination in patients transitioning fixed or unifixed bimatoprost 0.03%/timolol 0.5%. Adv Ther. 2011;28(8):661-670.
6. Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2005;140(2):242-250.
7. Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/ timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5):392-399.
8. Barnebey HS, Orengo-nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140(1):1-7.
9. Dunker S, Schmucker A, Maier H. Latanoprost/timolol f ixed combination study group. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007;24(2):376-386.
10. Inoue K, Okayama R, Higa R, Sawada H, Wakakura M, Tomita G. Ocular hypotensive effects and safety over 3 months of switching from an unfixed combination to latanoprost 0.005%/timolol 0.5% fixed combination. J Ocul Pharmacol Ther. 2011:27(6):581-587.